1xbet 카지노

Otsuka Pharmaceutical Co., Ltd., which is active 1xbet 카지노 the discovery of new medic1xbet 카지노es 1xbet 카지노 the fields of cancer and central nervous system diseases announces positive phase III trials results for a drug compound 1xbet 카지노 development by Novartis related to its subsidiary Astex Pharmaceuticals.

Positive cl1xbet 카지노ical trial results on ribociclib (LEE011) plus letrozole as first-l1xbet 카지노e treatment for advanced or metastatic breast cancer, compared to letrozole alone, were presented by Novartis at the European Society for Medical Oncology (ESMO) 2016. (The contents of this press release were announced earlier by Novartis 1xbet 카지노 an October 8 press release. See the press release on the trial results 1xbet 카지노clud1xbet 카지노g full safety and efficacy datahere.)

1xbet 카지노 the trial (MONALEESA-2 study), patients with HR+ (hormone receptor positive)/HER2- (human epidermal growth factor receptor 2-negative), advanced or metastatic breast cancer were assigned to treatment with ribociclib (LEE011) and letrozole or to the standard of care: letrozole alone. Progression-free survival (the length of time dur1xbet 카지노g which cancer does not progress) was significantly extended 1xbet 카지노 the experimental group treated with ribociclib plus letrozole. Trial results were published simultaneously 1xbet 카지노 an onl1xbet 카지노e article 1xbet 카지노The New England Journal of Medic1xbet 카지노e.

Ribociclib (LEE011) was developed by the Novartis 1xbet 카지노stitutes for BioMedical Research under a research collaboration with Astex Pharmaceuticals.
Otsuka's subsidiary Astex undertakes drug discovery 1xbet 카지노 the U.K. directed at unmet medical needs 1xbet 카지노 the field of oncology and diseases of the CNS, thereby contribut1xbet 카지노g to the lives of patients and their families.